Tacatuzumab Biosimilar – Anti-Alpha-fetoprotein mAb – Research Grade from ProteoGenix; catalogue PX-TA1906; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Tacatuzumab Biosimilar, also known as Anti-Alpha-fetoprotein mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Tacatuzumab. This biosimilar is a highly specific and potent therapeutic agent that targets the Alpha-fetoprotein (AFP) protein, which is overexpressed in various types of cancer. In this article, we will explore the structure, activity, and application of Tacatuzumab Biosimilar in detail.
Tacatuzumab Biosimilar is a recombinant humanized monoclonal antibody that is composed of two identical heavy chains and two identical light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL). The VH and VL domains together form the antigen-binding site, which is responsible for the specificity of the antibody.
The amino acid sequence of Tacatuzumab Biosimilar is highly similar to the original Tacatuzumab, with only a few differences in the constant domains. This ensures that the biosimilar has the same binding affinity and specificity as the original antibody.
Tacatuzumab Biosimilar specifically targets the AFP protein, which is a tumor-associated antigen that is overexpressed in various types of cancer, including hepatocellular carcinoma, ovarian cancer, and testicular cancer. The antibody binds to the AFP protein with high affinity and blocks its activity, leading to inhibition of tumor growth and progression.
In addition to blocking the activity of AFP, Tacatuzumab Biosimilar also activates the immune system to target and destroy cancer cells. This is achieved through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), where the antibody binds to cancer cells and triggers the immune cells to attack and kill them.
Tacatuzumab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various types of cancer. In a phase I clinical trial, the biosimilar was found to be safe and well-tolerated in patients with advanced hepatocellular carcinoma. In addition, it showed a significant reduction in AFP levels and tumor size in some patients.
The biosimilar is also being evaluated for the treatment of ovarian cancer and testicular cancer, where AFP is also overexpressed. In preclinical studies, Tacatuzumab Biosimilar has shown potent anti-tumor activity and synergistic effects when combined with other anti- cancer therapies.
Compared to the original Tacatuzumab, the biosimilar offers several advantages. Firstly, it is more cost-effective, making it more accessible to patients. Secondly, the biosimilar has a shorter development time and can be produced in larger quantities, ensuring a stable and consistent supply. Lastly, the biosimilar has a similar safety and efficacy profile as the original antibody, making it a reliable treatment option for patients.
In conclusion, Tacatuzumab Biosimilar – Anti-Alpha-fetoprotein mAb – Research Grade is a highly specific and potent monoclonal antibody that targets the AFP protein, which is overexpressed in various types of cancer. Its unique structure and activity make it a promising therapeutic agent for the treatment of hepatocellular carcinoma, ovarian cancer, and testicular cancer. With its advantages over the original antibody, Tacatuzumab Biosimilar has the potential to improve the treatment outcomes for cancer patients.
ProteoGenix catalogue number PX-TA1906. For research use only.
Target: Tacatuzumab Biosimilar – Anti-Alpha-fetoprotein mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Tacatuzumab Biosimilar – Anti-Alpha-fetoprotein mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
